Drug Approval | October 18, 2023
Glenmark receives ANDA approval for Apremilast Tablets
Glenmark's current portfolio consists of 188 products authorized for distribution in the US
Glenmark's current portfolio consists of 188 products authorized for distribution in the US
Apremilast Tablets, 10 mg, 20 mg, and 30 mg is a generic equivalent of reference listed drug (RLD) OTEZLA of Celgene.
Applications supported by positive results from the pivotal Phase 3 POETYK-PSO clinical trial program demonstrating superior efficacy of deucravacitinib over Otezla (apremilast)
Zydus' Apremilast tablets are indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy
Apremilast tablets are indicated for the treatment of adult patients with moderate to severe plaque psoriasis .
Subscribe To Our Newsletter & Stay Updated
